Table 1.
Patient disposition and baseline characteristics
| Parameters | Biosimilar ranibizumab (N = 103) |
|---|---|
| Age, years (mean ± SD) | 67.2 ± 9.02 |
| Gender | |
| Men | 64 (62.1) |
| Women | 39 (37.9) |
| Wet AMD subgroup, n (%)a | |
| Classic | 72 (69.9) |
| Occult | 13 (12.6) |
| Minimally classic | 8 (7.8) |
| Eye treated, n (%) | |
| Left | 50 (48.5) |
| Right | 53 (51.5) |
| Phakic vs. pseudophakic eye, n (%) | |
| Phakic eye | 46 (44.7) |
| Pseudophakic eye | 57 (55.3) |
| Treatment, n (%)a | |
| Treatment naïve | 77 (74.8) |
| Previously treated | 18 (17.5) |
| Baseline BCVA score, logMAR, mean ± SDb | 0.92 ± 0.6 |
| Baseline CSFT, µm, mean ± SDb | 430.83 ± 14.4 |
| Baseline IOP, mmHg, mean ± SDb | 14.92 ± 3.2 |
| Baseline SRFa | |
| Present, n (%) | 79 (82.3) |
| Absent, n (%) | 17 (17.7) |
| Baseline IRFa | |
| Present, n (%) | 63 (63.6) |
| Absent, n (%) | 36 (36.4) |
AMD age-related macular degeneration, BCVA best corrected visual acuity, CSFT central subfield thickness, IRF intraretinal fluid, SD standard deviation, SRF subretinal fluid, VEGF vascular endothelial growth factor
aData not available for 10 patients in wet AMD subgroup, 8 patients for treatment-naïve vs. previously treated eye, 7 patients for baseline SRF, and 4 patients for baseline IRF
bBaseline scores for BCVA available in 94 patients, CSFT in 85 patients, and IOP in 94 patients